Forscherdatenbank
Prof. Dr. Christoph Peters
University of Freiburg
Stefan-Meier-Straße 17
79104 Freiburg
Programm
Exploitation of Oncogenic Mechanisms (EOM)
Übersicht
Prof. Dr. Christoph Peters (director of the Institute for Molecular Medicine and Cell Research and Scientific Director of the Comprehensive Cancer Center Freiburg, and spokesperson of the Collaborative Research Center “Control of Cell Motility in Morphogenesis, Cancer Invasion and Metastasis” (SFB 850)) aims to investigate cancer invasion and metastasis taking cancer cell autonomous as well as non-autonomous processes into account. The analysis of pathways to elucidate the mechanisms underlying pathological cell motility in cancer and the investigation of the tumor microenvironment as an essential factor for survival, growth and tissue invasion and metastasis of carcinomas are in the focus of his research.
Proteolysis is a hallmark process during invasion and metastasis of solid cancers. The expression of the cysteine-type proteases cathepsin B and cathepsin X are correlated to poor prognosis of cancer patients. Genetic deficiency of these enzymes in cancer mice results in reduced tumor and metastatic burden. However, causal insights into the in vivo functions of cathepsins B and X in tumor progression are still missing. Therefore, the identification of cell types and the molecular networks in which cathepsins B and X are critical for cancer cell invasion and metastasis in mouse models is under ongoing investigation.
Tumour progression is caused by dysregulated intracellular signaling, but also by altered interaction of cells with their environment. Both processes are connected to each other as modifications of signaling and metabolic pathways caused by oncogenic events within the tumor cell are contributing to the establishment and dynamic remodeling of the tumor microenvironment, e.g. by inducing proteolytic activities and secreting signaling molecules that address stromal, endothelial and immune cells. Therefore, the tumor microenvironment has drastic effects on the establishment and progression of a tumor. Research groups at the Institute for Molecular Medicine and Cell Research are working on cell cultures and and transgenic animal modles to obtain novel insights by re-building the tumor microenvironment in a well-defined experimental settings that also allow its multi-parameter monitoring in real time.
Prof. Dr. Christoph Peters works in close cooperation with other DKTK investigators in Freiburg. Overlaps are existing with the research of Prof. Dr. Thomas Reinheckel (protease network), Prof. Dr. Melanie Börries (systems biology of cellular microenvironment), Prof. Dr. Oliver Schilling (disease specific proteome profiles) and Prof. Dr. Tilman Brummer (B-raf Signaling Pathway).
DKTK Junior Group Leader for Cancer Systems Biology
Single-cell approaches have not only revealed a wide variety of cell states, characterized by cells exhibiting striking differences in their transcriptional profile, but have also illuminated the mechanisms underlying state transitions in health and disease. Cellular plasticity and adaptive state changes have recently emerged as a basis for therapeutic resistance in cancer, and a better understanding of how cell state transitions are regulated is critical to develop therapeutic approaches that can overcome therapy resistance.
Our research focuses on understanding the mechanisms driving non-genetic cellular heterogeneity and therapy resistance in malignancy. Using novel single-cell sequencing approaches, we seek to develop new experimental and computational strategies to define altered cell states in both, cancer and immune cells. Our aim is to leverage a data driven strategy combined with single cell genomics and systems biology to address the challenges posed by heterogeneity in cancer, and to develop new strategies to overcome it, with the aim of translating laboratory-based findings into the clinic.